Clinical trial · Interventional
uPAR-PET/MRI in Glioblastoma Multiforme
NCT02945826CI-TRIAL-00032434unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / MRI molecular imaging of glioblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| One injection of 68Ga-NOTA-AE105 | Drug | — | UNRESOLVED |
| PET/MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- uPAR PET/MRI
- description
- One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
- interventionNames
- Drug: One injection of 68Ga-NOTA-AE105
- Device: PET/MRI
Primary outcomes (2)
- measure
- uPAR PET/MRI imaging of uPAR expression
- timeFrame
- 1 hour
- description
- Standard uptake values (SUVs) of 68Ga-NOTA-AE105 evaluated on uPAR-PET/MRI scan performed within 1 hour following injection of 68Ga-NOTA-AE105, compared with immunohistochemistry of uPAR (semiquantitative)
- measure
- uPAR PET/MRI prognostic factor for overall survival
- timeFrame
- 36 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients where imaging with MRI or CT is suspicious of having glioblastoma multiforme, and patients, and who is referred for stereotactic biopsy, chemotherapy or surgery * The participants must be capable of understanding and giving full informed written consent * age above 18 years Exclusion Criteria: * Pregnancy * Lactation/breast feeding * Age above 85 years old * Weight above 140 kg * Known allergy towards 68Ga-NOTA-AE105
References
Publications (1)
- DERIVEDAzam A, Kurbegovic S, Carlsen EA, Andersen TL, Larsen VA, Law I, Skjoth-Rasmussen J, Kjaer A. Prospective phase II trial of [68Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy. EJNMMI Res. 2024 Oct 29;14(1):100. doi: 10.1186/s13550-024-01164-9. PMID 39472354